Bennett Osantowski

Jun 20, 2024 | onlinelibrary.wiley.com | Danai Dima |Nerea Lopetegui-Lia |Olisaemeka Ogbue |Bennett Osantowski

1 INTRODUCTION Over the last decade, significant drug advancements have radically shifted the treatment paradigm of melanoma leading to improved patient outcomes.1-3 Immunotherapy (IO) with anti-CTLA4 and anti-PD1 monoclonal antibodies, as well as targeted therapy (TT) with BRAF/MEK inhibitors, demonstrated improved survival of patients with metastatic disease.4-8 More recently, these treatments have been studied in the adjuvant (adj) setting for resected stage III/IV melanoma, also showing...